Get started

PFIZER

Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience?Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience? $28.90 in Sight? 📈 At $24.04 (+0.04%), PFE offers a compelling entry with its low P/E of 12.72 and robust 7.15% dividend yield, trading well below analyst targets of $28.90 (20% upside potential)—could resilient economic forecasts boost healthcare demand and spark a rally? 🚀 **Fundamental Analysis** Pfizer boasts EPS (TTM) of $1.89 and revenue (TTM) of $63.83B, with a PEG ratio of 0.96 signaling undervaluation relative to growth prospects; DCF models suggest intrinsic value above current levels given strong cash flows of $16.02B, though patent expirations weigh on margins. - **Positive:** High dividend yield supports income-focused portfolios; diversified pipeline in oncology and vaccines drives long-term revenue stability. - **Negative:** Elevated enterprise value/EBITDA at 9.15 reflects debt from acquisitions; regulatory hurdles could delay new approvals. **SWOT Analysis** **Strengths:** Broad product portfolio and global reach; strong R&D investment. **Weaknesses:** High debt levels post-acquisitions; dependency on blockbuster drugs. **Opportunities:** Expanding into emerging markets amid economic growth; AI-driven drug discovery partnerships. **Threats:** Generic competition; geopolitical tensions impacting supply chains. **Technical Analysis** Chart shows consolidation in a tight range with emerging bullish momentum. Price: $24.04, VWAP $24.10. Key indicators: - RSI: 45 (neutral, room for upside without overbought risk). - MACD: Positive crossover signaling building momentum. - Moving Averages: 50-day at $25 (potential breakout level), 200-day at $26 (long-term trendline). Support/Resistance: Support at $23, resistance at $25. Patterns/Momentum: Ascending triangle forming, favoring bulls on volume increase. 📈 Bullish | ⚠️ Bearish. **Scenarios and Risk Management** - **Bullish:** Entry above $25 on volume, DCA in dips to average down for 20% upside to targets. - **Bearish:** Drop below $23 on weak earnings, exit positions. - **Neutral:** Sideways trade between support/resistance amid macro waits. Risk Tips: Set stops at 5% below entry, limit position to 2-3% of portfolio, diversify across sectors, and apply DCA to mitigate volatility. ⚠️ **Conclusion/Outlook** Bullish bias if economic resilience sustains healthcare spend. Watch Fed remarks. Fits value theme with #Economy upside. Take? Comment!
NYSE:PFELong
by DCAChampion
1
Pfizer and Pharma Stocks Rise After Trump DecisionPfizer Inc. (PFE) and Other Pharmaceutical Stocks Rise Following Trump’s Decision According to media reports, US President Donald Trump launched a website allowing Americans to purchase medicines directly. He announced that Pfizer would offer some of its drugs on this platform and introduce new medicines to the US market at reduced prices. Trump added that his administration is working with other companies, including Eli Lilly, to reach “similar agreements.” Reports state that Pfizer’s deal with the Trump administration will enable patients to receive significant discounts. In return, the company will receive a three-year exemption from any tariffs. The news pushed pharmaceutical stocks to the top of yesterday’s gainers list: → Pfizer Inc. (PFE) rose by 6.8% → Merck & Co Inc. (MRK) rose by 6.8% → Eli Lilly and Co. (LLY) rose by 5.0% Technical analysis of the PFE chart The chart indicates that: → In the long term, PFE’s share price remains in a bearish trend, highlighted by the descending orange channel. → However, in April the stock reached its lowest level in nearly 13 years, after which the price began showing an upward trajectory, forming higher highs and higher lows within the ascending blue channel. A strong fundamental driver yesterday caused PFE’s share price to rebound sharply from the lower boundary of the blue channel towards its median, encountering little resistance when breaking through the September local barrier at $24.75. It is possible that positive market sentiment will persist and be leveraged by bulls to extend the rally. However, the real test of their resolve might come at resistance near the summer highs around $26.00. A more substantial obstacle might lie in the $27–27.50 area, where multiple resistances converge, including: → the upper boundaries of both the blue and orange channels; → key highs from the first half of 2025. Nonetheless, assuming the fundamental backdrop continues to be supported by positive news on progress in cancer treatments (Pfizer is conducting large-scale developments in this area, aided by its acquisition of Seagen, a pioneer in antibody-drug conjugates, or ADCs), this could lead to an attempt to break the long-term downward trend as early as this year. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:PFE
by FXOpen
Pfizer’s Next Big Shot: COVID Levels Back on the Table?Huge Crisis or Groundbreaking Discovery? This scenario suggests that once the running flat correction is completed — which we are very close to — the price is set to explode by at least 300% in the coming years (see red box). Why do I think so? • The running correction is approaching its final target zone, meaning the price should soon stop, reverse, and start pumping. • After the correction phase comes the impulse, and we are expecting Wave 3 — the most volatile and dynamic wave of all. • Minimum target: $108 It’s only a matter of sooner or later.
NYSE:PFELong
by Jossim_Elliott
1
Pfizer's Weekly Supply Rejection Points to Possible TriggerPfizer Inc. recently retested a significant weekly supply zone, experiencing a rejection that suggests the market may revisit this level again. This retest could serve as a setup for a potential decline toward the daily demand area. Additionally, seasonal analysis indicates that the stock may continue its bearish trend, supporting the possibility of further downside movement. Traders should monitor these technical levels and seasonal signals for potential trading opportunities aligned with the ongoing bearish outlook. ✅ Please share your thoughts about PFE in the comments section below and HIT LIKE if you appreciate my analysis. Don't forget to FOLLOW ME; you will help us a lot with this small contribution.
NYSE:PFEShort
by FOREXN1
3
The Collaborative Edge: Pfizer's Innovation Secret? Pfizer's success in the biopharmaceutical industry hinges on its internal capabilities and a strategic embrace of external collaboration. This proactive approach, spanning diverse technological frontiers, fuels innovation across its operations. From partnering with QuantumBasel and D-Wave to optimize production planning using quantum annealing, to collaborating with XtalPi to revolutionize drug discovery through AI-powered crystal structure prediction, Pfizer demonstrates the tangible benefits of cross-industry partnerships. These initiatives showcase a commitment to exploring cutting-edge technologies to enhance efficiency and accelerate the identification of promising drug candidates, ultimately improving patient outcomes and strengthening Pfizer's competitive position. The article highlights specific examples of Pfizer's collaborative endeavors. The Pfizer Healthcare Hub in Freiburg acts as a catalyst, connecting internal needs with external innovation. The successful proof of technology in production planning using quantum annealing resulted in significant time and resource savings. Furthermore, the partnership with XtalPi has dramatically reduced the timeframe for determining the 3-D structure of potential drug molecules, enabling faster and more efficient drug screening. These collaborations exemplify Pfizer's strategic focus on leveraging specialized expertise and advanced technologies from external partners to overcome complex challenges in the pharmaceutical value chain. Beyond these specific projects, Pfizer actively engages with the broader quantum computing landscape, recognizing its transformative potential for drug design, clinical studies, and personalized medicine. Collaborations with technology giants like IBM and fellow pharmaceutical companies underscore the industry-wide interest in harnessing the power of quantum computing. While the technology is still in its early stages, Pfizer's proactive participation in this collaborative ecosystem positions it at the forefront of future healthcare breakthroughs. This commitment to synergy, from basic research to market research, underscores a fundamental belief in the power of working together to drive meaningful advancements in the pharmaceutical industry.
NYSE:PFELong
by UDIS_View
PFE 1H Long Swing Conservative Trend TradeConservative Trend Trade + long impulse + SOS level + support level + 1/2 correction + biggest volumed Sp Calculated affordable stop limit 1 to 2 R/R take profit before 1/2 of the Month Expandable to 1/2 of the Year Daily Trend: "+ long impulse + neutral zone + close to 1/2 correction" Monthly CounterTrend "- short balance + unvolumed expanding ICE + volumed 2Sp- + weak test" Yearly Trend "+ long impulse + 1/2 correction + exhaustion volume?" Will add more if corrects to 1/2 of 1H wave.
NYSE:PFELong
by MishaSuvorov
Pfizer Ltd. - Short Position AnalysisChart Overview: The chart indicates that the stock is in a clear downtrend, following a descending channel pattern. The price is nearing a key horizontal support level (marked in black), and a breakdown below this level may present a shorting opportunity. Trade Setup for Short Position: 1.Entry Trigger: Below ₹5,028 on a daily closing basis. 2.Targets: Target 1: ₹4,885 (first demand zone). Target 2: ₹4,760 (strong support and lower boundary of the descending channel). 3.Stop Loss: Above ₹5,187 (recent swing high and red-dotted resistance level). 4.Risk-Reward Ratio: Ensure a favorable ratio of at least 1:2. Alternate Scenario: If ₹5,028 holds as support, the stock might see a pullback toward ₹5,187, where selling pressure could resume.
NSE:PFIZERShort
by AngshumanSaikia
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by MorMedia
2
PFIZER, targeting $50! Upside Prospect ON!PFE weekly data is conveying significant accumulation at the current price range. Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term. The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge. Expect some significant bounce from the current range with initial target to $50. Weekly higher lows on histogram has been registered. Trend shift is about to commence. First Bubble up volume appearance in almost 2 months. Spotted at 38.0 TAYOR Safeguard capital always.
NYSE:PFELong
by JSAL
8
$PFE | Allocation/Buy Trade | Market Exec |Technical Confluences: - Price is in Oversold Conditions in D1 timeframe - Price action bouncing off 150% Fibo Extension - Price is trying to go back above the Interest Zone to give some bullish momentum to the stock Fundamental Confluences: -Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry - They had a good response on a testing of their recent respiratory drug - Value? ---- Health sector in your Portfolio will never be wrong with the global aging population. I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE. Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown. -----
NYSE:PFELong
by weekendanalyst
Pfizer !!! low risk , 20% Gain till next month ?? Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week could boost the stock price to $30 by next month. You can refer to the chart for trade stop and stop-loss points. Disclaimer: This information or service is for informational purposes only and is not intended to be personal financial advice #pfizer
NYSE:PFELong
by S_INV28
1
Trade Like A Sniper - Episode 16 - Pfizer - (5th June 2024)This video is part of a video series where I backtest a specific asset using the TradingView Replay function, and perform a top-down analysis using ICT's Concepts in order to frame ONE high-probability setup. I choose a random point of time to replay, and begin to work my way down the timeframes. Trading like a sniper is not about entries with no drawdown. It is about careful planning, discipline, and taking your shot at the right time in the best of conditions. A couple of things to note: - I cannot see news events. - I cannot change timeframes without affecting my bias due to higher-timeframe candles revealing its entire range. - I cannot go to a very low timeframe due to the limit in amount of replayed candlesticks In this session I will be analyzing PFE (Pfizer), starting from the 4-Month chart. - R2F
NYSE:PFE
by Road_2_Funded
Pfizer implements $1.5bn cost-cutting initiative. Idea 27/05/24Pfizer Inc. (PFE) has announced a new multi-year plan to reduce operational costs by approximately 1.5 billion USD by the end of 2027. This initiative is in addition to a previously announced 4 billion USD cost reduction strategy in response to decreased investments and a sharp decline in sales from its COVID-19 vaccine. Amid these challenges, Pfizer has actively restructured its operations, including acquiring cancer drug manufacturer Seagen for 43 billion USD, aiming to diversify and strengthen its product portfolio. Despite these financial adjustments, Pfizer has raised its full-year earnings forecast following better-than-expected earnings in Q1. These results were partly attributed to the successful implementation of cost-saving measures. To bolster its financial standing, the company focuses on operational efficiency, restructuring its network, and enhancing its product portfolio. Given this backdrop, let's examine the potential trading opportunities for Pfizer Inc. (NYSE: PFE): On the Daily (D1) timeframe, Pfizer's stock shows a resistance level at 29.65 USD and support at 28.45 USD. The resistance line of the ongoing downtrend has been breached, suggesting a potential shift in market sentiment. If the trend reverses downward, a possible target might be 25.30 USD. If the current uptrend persists, a short-term target is 31.90 USD upon rebounding from the 29.65 USD resistance level. For a medium-term strategy, the stock price could reach 34.10 USD if the upward momentum continues. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:PFE
by RoboMarkets